Insulin Syringes: An ISO 8537 Specification Guide Distinct from ISO 7886 Syringes

When a hospital procurement team, clinical engineering department, or medical distributor receives a tender request for insulin delivery supplies, the most critical initial specification decision is establishing the governing product standard. A frequent and costly error in healthcare procurement is treating all manual plastic syringes as generic hypodermic devices and applying specifications copied from general hypodermic purchasing schedules.

The international consensus framework maintains an unambiguous boundary between general hypodermic injection devices and dedicated insulin syringes. Under ISO 7886-1:2017 (Sterile hypodermic syringes for single use — Part 1: Syringes for manual use), which is recognized completely by the U.S. Food and Drug Administration (FDA) under Rec# 6-404, the public scope explicitly excludes syringes intended for use with insulin and instructs technical buyers to reference ISO 8537. Our companion technical reference on sterile hypodermic syringe specifications occupies millilitre-scale empty sterile manual syringes. That page does not govern insulin unit scale, concentration matching, or ISO 8537 type fields.

The designated particular standard for this product family is ISO 8537:2016 (Sterile single-use syringes, with or without needle, for insulin; Third edition, confirmed in 2021 and currently under revision as ISO/FDIS 8537). ISO 8537 specifies empty, sterile, single-use syringes made of plastic materials, with or without needles, intended solely for the injection of insulin, filled by the end user, for use immediately after filling. The public introduction states that the standard does not specify construction materials because selection depends on the manufacturer's design, process, and sterilization method. Public copy may use scope, type names, and FDA recognition status; it is not a license to paste paywalled graduation, dead-space, or accuracy tables.

Procurement officers must recognize the strict product boundaries defined in ISO 8537 Clause 1. The standard applies solely to manual syringes filled by the end user for immediate injection. It explicitly excludes four categories of injection consumables:

• Single-use glass syringes: ISO 8537 covers plastic materials and excludes single-use glass syringes.

• Syringes for power-driven syringe pumps: ISO 8537 excludes syringes for use with power-driven syringe pumps. Those SKUs are a different particular-standard job from this page and from the published ISO 7886-1 millilitre page.

• Manufacturer-prefilled syringes: Prefilled devices containing insulin at the point of manufacture are regulated as combination drug-device products, biological products, or pen injectors under the ISO 11608 series.

• Syringes intended to store insulin after filling: ISO 8537 excludes syringes intended to be stored after filling, including a kit intended for filling by a pharmacist. Immediate use after filling is a labeled intended-use boundary, not a qualification to use the barrel as a storage container.

flowchart TD
    A["Procurement Requisition: Manual Injection Consumables"] --> B{"Is the device intended for Insulin?"}
    B -- "No: General Medications / Saline" --> C["ISO 7886-1:2017 (FDA Rec# 6-404 Complete)"]
    C --> C1["Scale: Volumetric Milliliters (mL)"]
    C --> C2["21 CFR 880.5860 Product Code FMF"]
    B -- "Yes: Subcutaneous Insulin" --> D{"Administration Architecture"}
    D -- "Manual Syringe (Filled by End User)" --> E["ISO 8537:2016 (FDA Rec# 6-364 Partial)"]
    E --> E1["Scale: Insulin units (one labeled concentration)"]
    E --> E2["21 CFR 880.5860 FMF (+ MEG if Safety Shield)"]
    D -- "Prefilled Cartridge / Mechanical Pen" --> F["ISO 11608 Series (FDA Rec# 6-478)"]
    F --> F1["Product Code NSC (Injector, Pen)"]

In the United States, medical devices are classified by risk class under Title 21 of the Code of Federal Regulations. An insulin syringe does not have an isolated, bespoke regulation number; rather, it is regulated as a piston syringe under 21 CFR 880.5860. Regulation 880.5860 identifies a piston syringe as a device intended for medical purposes that consists of a calibrated hollow barrel and a movable plunger, with a male connector (nozzle) at one end for fitting the female connector (hub) of a hypodermic single-lumen needle, used to inject fluids into, or withdraw fluids from, the body. The generic type is designated Class II (performance standards) and requires premarket notification (510(k)) clearance prior to commercial distribution.

The operational specification benchmark utilized by FDA reviewers and device manufacturers remains the FDA's landmark guidance document: Guidance on the Content of Premarket Notification [510(k)] Submissions for Piston Syringes (issued April 1993). It was written before the February 27, 1997 Good Guidance Practices (GGP) regulations, does not bind FDA or the public, and remains the live public U.S. field list for insulin unit scale, the U100 legend, orange needle covers, and the 801.109(b)(1) exception. An alternative approach may be used if it satisfies the applicable statute and regulations. Content is current as of March 27, 2018.

Hospital procurement schedules and tender specifications should incorporate the five core device description and labeling criteria established in the 1993 guidance:

1. Scale Graduation in Units: The barrel scale should be graduated in units of insulin (not millilitres), easily legible, with markings of a color that contrasts clearly with the syringe. The ink or pigment should not rub off during use.

2. Prominent Barrel Concentration Legend: For typical U.S. U-100 files, the barrel should bear the concentration legend named in the guidance, specifically "For use with U100 insulin only". That is a U-100 labeling field. Do not invent a matching U-40 legend unless the 510(k) or label actually carries it.

3. Color-Coded Orange Needle Covers: Needle covers for insulin syringes should be color-coded orange for visually impaired users. That is a U.S. guidance field, not FDA recognition of ISO 8537 Section 5.3, and it is not a universal color for every concentration: K193273 labels red for U-40 and orange for U-100; K151870 uses a green shield for dedicated U-500.

4. Sterility and Safety Labeling Statements: Labeling should include identity (type, size, needle gauge and length if applicable) and the statements "sterile, single use only, nonpyrogenic, nontoxic".

5. Prescription Statement Exemption: The guidance lists the prescription statement under 21 CFR 801.109(b)(1) as applicable except for insulin syringes. That exception is not a universal OTC rule. Copy the labeled Rx versus OTC field: K201044 is over-the-counter; K221045 is prescription use; FDA's 8 July 2016 U-500 communication states that approved syringes for Humulin R U-500 vials are available with a prescription and should be co-prescribed with U-500 insulin.

Technical auditors and procurement specialists must also distinguish historical guidance text from current regulatory reality. Two specific statements in the April 1993 guidance are stale relative to modern public records and must not be treated as restrictive regulatory barriers:

• Barrel Volume Limits: The 1993 guidance stated under Device Description that "The volumes for the standard syringes are 1.0 ml (100 units), and 0.5 ml (50 units)". Current cleared files—including K190054, K201044, and K223376—include 0.3 mL alongside 0.5 mL and 1.0 mL. Half-unit marks appear on K190054's 0.3 mL SKU; they are a labeled increment field, not a universal 0.3 mL rule and not dosing instructions. Specify the labeled nominal volume rather than treating the 1993 0.5/1.0 mL pair as a closed catalogue.

• Stale Regulatory Citation: The 1993 guidance cites "801.403 INSULIN SYRINGES" for special labeling rules. Title 21 of the eCFR contains no section 801.403; Subpart H (Special Requirements for Specific Devices) currently begins at 21 CFR 801.405. Quality contracts and regulatory filings should reference 21 CFR 880.5860 and the 1993 guidance fields directly rather than citing a nonexistent CFR clause.

A frequent breakdown in healthcare supply chain management occurs when hospital ERP systems or distributor catalogs classify all injection consumables under a single generic category code. Under FDA product classification, devices governed by 21 CFR 880.5860 are subdivided into distinct product codes that reflect different technological characteristics, consensus standards, and review processes.

Evaluating manufacturer 510(k) summary documentation reveals four distinct product codes that procurement teams must not conflate:

Understanding these code distinctions is essential when verifying manufacturer regulatory submissions. For example, in K223376 (clearing the Cardinal Health Monoject Magellan Insulin Safety Syringe), the manufacturer declared three concurrent product codes: MEG for the integral needle-shielding mechanism, FMF for the calibrated piston syringe barrel, and FMI for the integrated stainless-steel needle cannula. Conversely, K201044 (Chirana Insulin Syringe) declared FMF and FMI because it features an attached needle without a sharps-shielding mechanism. A tender calling for sharps-safety compliance cannot accept an FMF-only file that lacks MEG classification and ISO 23908 bench verification.

The public introduction to ISO 8537 states that an individual syringe should be graduated and labelled for exactly one concentration of insulin. Serious problems can result if a syringe is used with a different concentration. That is a specification-matching field, not injection or conversion advice.

Procurement officers frequently ask why the FDA's consensus standards database designates recognition of ISO 8537:2016 (Rec# 6-364) as "Partial". The FDA's Supplemental Information Sheet (SIS) explicitly states that Section 5.3 (Colour coding) of ISO 8537 is NOT recognized by the agency. The rationale is direct: the international color schemes described in ISO 8537 Section 5.3 conflict with the established U.S. practice—codified in Section II.D of the April 1993 guidance—requiring bright orange needle covers on U-100 insulin syringes. A U.S. hospital tender or supplier contract cannot cite ISO 8537 Section 5.3 as FDA-recognized evidence. Specify the labeled cap or shield color together with the labeled concentration, using the 1993 orange-cover field for typical U-100 SKUs.

Named 510(k)s show three concentration identities. These rows are labeled examples, not interchangeable SKUs and not a closed color law:

The U-500 pairing is a labeled identity, not a conversion worksheet. FDA's 8 July 2016 Drug Safety Communication records that the Humulin R U-500 vial had been available since 1994 with no dedicated delivery device, and announces clearance of the dedicated BD U-500 Insulin Syringe (K151870).

FDA's 8 July 2016 communication states that this dedicated syringe is the only device approved for use with the Humulin R U-500 insulin vial, that dose conversions with a U-100 insulin syringe or a tuberculin (volumetric) syringe are no longer needed, and that approved syringes for U-500 vials are prescription and should be co-prescribed with U-500 insulin. K151870 is a 0.5 mL syringe with unique U-500 scale markings, 31G x 6 mm needle, a green needle shield, and a green U-500 symbol; packaging graphics are designed to match U-500 vial labeling. Humulin R U-500 is also available as a prefilled pen, which ISO 8537 excludes. Do not specify a U-100 orange-cap SKU or a millilitre tuberculin syringe as a substitute.

ISO 8537 Clause 4 categorizes insulin syringes into eight distinct design configurations (Types 1 through 8) based on fluid connection geometry and primary packaging architecture. Specifying an insulin syringe requires defining the appropriate ISO type:

• Types 1 and 2 (Luer Conical Fitting without Needle): Syringes featuring a standard 6% (Luer) male fitting intended to mate with a detachable needle. Type 1 is unit-packaged; Type 2 features protective end caps over the nozzle and plunger.

• Types 3 and 4 (Luer Conical Fitting with Detachable Needle): Syringes supplied with an unattached or pre-attached detachable hypodermic needle. Type 3 is unit-packaged; Type 4 utilizes protective end caps.

• Types 5 and 6 (Non-Luer Fitting with Non-Detachable Needle): Syringes with a fitting other than 6% Luer and a needle not intended to be detached. Type 5 is unit-packaged; Type 6 uses protective end caps.

• Types 7 and 8 (Integrated Fixed Needle Tube): Syringes where the needle cannula is embedded or staked directly into the syringe barrel during molding, eliminating the needle hub. Type 7 is unit-packaged; Type 8 uses protective end caps.

Public 510(k) clearance summaries explicitly cite these ISO configuration types. For instance, K193273 (Promisemed) specifically designates its cleared product lines as Type 7 and Type 8 fixed-needle syringes. That type numbering is labeled on K193273. Do not assign Type 7/8 to every permanently attached needle: K190054 describes a snap-fit needle hub on 0.3 mL and 0.5 mL and an integral barrel on 1 mL, without an ISO type number. Dead-space limits remain paywalled; ask for the labeled type and for dead-space evidence without copying ISO numeric tables.

However, procurement teams must not assume that every insulin syringe has an integrated needle. In K221045, manufacturer Berpu Medical cleared a 1.0 mL U-100 insulin syringe without a needle. This device incorporates a Luer-lock connector evaluated under ISO 80369-7:2021 (FDA Recognized Consensus Standard Rec# 5-133: Small-bore connectors for liquids and gases in healthcare applications — Part 7: Connectors for intravascular or hypodermic applications). The K221045 device is cleared under 21 CFR 880.5860 (FMF) for insulin aspiration and injection in conjunction with a separate sterile hypodermic needle. When the SKU is a Luer insulin syringe without a needle, record the connector family (ISO 80369-7 Rec# 5-133) as a field. K221045 is still an ISO 8537 product if so labeled; it is not an ISO 7886-1 general hypodermic syringe, not an IV administration set (21 CFR 880.5440), and not an ENFit/NRFit device.

The table below copies labeled fields from five public 510(k) summaries. Gauge, length, increment, type, SAL, and Rx versus OTC are file-specific. K201044 also lists ISO 7886-1 as an additional recognized standard; that related hypodermic reference does not move the SKU onto the published ISO 7886-1 page.

Copy sterility as labeled. The 1993 guidance's sterility attachment asks 510(k)s for the sterilization method and the SAL the firm intends to meet, and states that an SAL of 10^-6 is required for devices that contact normally sterile areas of the body. Named insulin files that publish an SAL use 10^-6 (K201044, K221045, K223376, K151870). Do not treat one file's modality as a family default.

Regulatory filings confirm two primary sterilization modalities for insulin consumables:

• Ethylene Oxide Gas (EO): Declared in accordance with ISO 11135 on K201044 and K221045, both to SAL 10^-6. K221045 also cites ISO 10993-7 for EO residuals. Ask for the labeled modality, SAL, and residual evidence; do not assume every insulin SKU is EO-sterilized.

• Ionizing radiation (gamma on named files): Declared in accordance with ISO 11137 on K190054 (ISO 11137-1/2/3 cited) and as gamma radiation on K223376 (ISO 11137-2 cited, SAL 10^-6) and K151870 (gamma; SAL 10^-6; ISO 11737 microbiological methods cited, not ISO 11137). Ask which radiation standard and SAL are labeled.

For safety-engineered devices bearing product code MEG, the live MEG classification record lists ISO 23908 First edition 2011-06-11 (Rec# 6-273) and Second edition 2024-12 (Rec# 6-507) and does not list Rec# 6-364 ISO 8537. K223376 describes a shield that extends, fully covers, and permanently locks over the needle, with one-handed activation; that summary does not name ISO 23908. A safety insulin syringe therefore has two evidence layers: ISO 8537 for the insulin syringe plus the sharps-protection evidence actually declared. Do not treat MEG, FMF, and FMI as interchangeable SKUs.

In institutional quality management, establishing a comprehensive quality agreement with consumable vendors is paramount. As explored in our dedicated guide on quality agreements for consumable suppliers, contracts should require pre-implementation notice for changes that affect concentration, unit scale, cap or shield color, needle gauge and length, connector family, or sterile barrier. K221045 lists polydimethylsiloxane as the lubricant on that Luer SKU; treat lubricant identity as a labeled material field to put in the quality agreement, not as a universal formulation.

Furthermore, package integrity and transport stability must be verified. In accordance with principles detailed in our analysis of labeled storage and transport for medical consumables, copy the labeled storage and distribution evidence rather than inventing a temperature band. K221045 cites ASTM D4169 shipping simulation and a 5-year labeled shelf life; K201044 validates 5 years for single-unit packaging and 2 years 4 months for multi-unit packaging. Shelf life is a labeled row, not a 3-year minimum.

To maintain absolute regulatory and editorial integrity, this technical specification establishes clear analytical boundaries regarding what it will not decide:

• No Clinical Dosing or Injection Instructions: This guide does not calculate insulin doses, convert between concentrations, or select a syringe for a named patient. Those questions belong in labeled indications and clinical protocols, not this RFQ.

• No Brand Ranking or Equivalent Claims: This publication does not endorse or rank specific syringe manufacturers (such as BD, Terumo, Chirana, or Cardinal Health). Substantial equivalence determinations in FDA 510(k) summaries represent manufacturer-sponsored legal demonstrations, not independent comparative evaluations by this guide.

• No Disclosure of Paywalled Numeric Tolerances: In compliance with international copyright standards, this document does not reproduce proprietary tables, exact dimensional engineering drawings, or Annex H graduation tolerance matrices from paywalled ISO publications.

Procurement managers, value-analysis committees, and medical distributors can utilize the following structured checklist when assembling Request for Quotation (RFQ) packages, evaluating vendor bids, or drafting annual supply agreements for manual insulin syringes:

1. Governing Particular Standard & Edition: Specify compliance with ISO 8537:2016 (or latest confirmed edition; track ISO/FDIS 8537). Stipulate that while general hypodermic ISO 7886-1 citations may appear as secondary references, ISO 8537 is mandatory for the insulin intended use.

2. FDA Classification & Product Codes: Require proof of clearance under 21 CFR 880.5860 (FMF). If an attached needle is supplied, confirm FMI (21 CFR 880.5570). If an anti-needlestick safety shield is required by occupational health policy, mandate product code MEG with supporting test data to ISO 23908.

3. Calibrated Insulin Concentration: State the labeled concentration (U-40, U-100, or a dedicated U-500 SKU) and require a matching unit scale. For U-100, require the 1993 guidance legend "For use with U100 insulin only" when that is the labeled identity. Do not treat U-40, U-100, and U-500 syringes as equivalent.

4. Needle Cap / Shield Concentration Coding: Specify the labeled cap or shield color with the concentration: orange on typical U.S. U-100 files (1993 guidance; K190054; K223376); red for U-40 on K193273; green for dedicated U-500 on K151870. Do not treat ISO 8537 Section 5.3 as FDA-recognized, and do not reuse ISO 6009 gauge colors as concentration coding.

5. Barrel Capacity & Graduation Increments: Specify labeled nominal volume (current files include 0.3, 0.5, and 1.0 mL) and the labeled increment on that SKU. Half-unit marks on K190054 0.3 mL are not a universal 0.3 mL rule. Reject a millilitre tuberculin scale as a substitute insulin syringe.

6. Connector & Needle Architecture: Specify the labeled ISO 8537 type. Type 7 and Type 8 are declared on K193273. Do not assume every insulin syringe is Type 7/8. If the SKU has no needle, record the Type 1/2 Luer configuration and ISO 80369-7 when declared, as on K221045.

7. Sterility Assurance & Shelf Life: Copy labeled sterility: sterile / single-use / nonpyrogenic as labeled; sterilization modality (EO versus radiation) and SAL if labeled; shelf life as labeled (K221045 5 years; K201044 5 years single-unit / 2 years 4 months multi-unit). Do not impose a 3-year minimum that would contradict a labeled multi-unit shelf life.

8. Vendor Change Notification: Incorporate mandatory pre-implementation change notice clauses in supplier quality agreements, forbidding unannounced changes to needle suppliers, barrel polymers, scale ink chemistry, or lubricants.

Procurement contracts and institutional formularies should establish periodic regulatory freshness audits. Formularies must be reviewed whenever any of the following regulatory triggers occur: (1) publication of ISO 8537 Fourth Edition (ISO/FDIS 8537); (2) updates to FDA Recognized Consensus Standard Rec# 6-364 or Rec# 6-404; (3) replacement or GGP-updating of the April 1993 FDA Piston Syringe Guidance; (4) amendments to 21 CFR 880.5860 or 880.5570; (5) revisions to FDA recognition of ISO 23908 editions under product code MEG; or (6) updates to FDA safety communications regarding dedicated U-500 syringe-vial pairing.